New biopharm pumps with extensive documentation package

Article

Pharmaceutical Technology Europe

Alfa Laval has added two new biopharm pumps to its offering and can now meet a wider selection of customer needs at differentiated prices.

Two new pumps have now been added to the Alfa Laval range for the biopharm industry, supported by the Alfa Laval Q-doc documentation package. The SolidC UltraPure centrifugal pump and the MR UltraPure liquid ring pump join the well-known LKH UltraPure pump range, meeting a wider selection of customer needs at differentiated prices.

When designing and developing products for the biopharm industry, Alfa Laval does what it takes — and more — to ensure consistent performance and prevent contamination. From material selection to product performance, the UltraPure range meets the most stringent needs and standards, as laid out clearly in the Alfa Laval Q-doc documentation package.

Comprehensive documentation package
Step by step all products are being released with the Alfa Laval Q-doc product documentation, which provides biopharm companies with full transparency regarding sourcing, production and supply chains, and makes it easy to trace even the slightest change in materials or manufacturing procedures. Q-doc is based upon Good Documentation Practice (GDP) and comprises equipment manuals, factory acceptance and performance tests, quality and manufacturing procedures, relevant material certificates and all necessary parts and service information.

Biopharm pump overview

Contact
Contact details to Alfa Laval sales companies around the world can be found on www.alfalaval.com/biopharm

Per-Åke Ohlsson, head of Alfa Laval’s Market unit Pharma
Phone: +46 46 36 70 00
E-mail:

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content